加载中
NASDAQHealthcareBiotechnology
最新数据
US$26.58
+US$2.09 · +8.53%
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
前收盘价
US$26.58
+US$2.09 · +8.53%
盘中时间采用ET。市场数据可能有所延迟。
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
日内区间
当前US$26.58
52周区间
当前US$26.58
盘中时间采用ET。市场数据可能有所延迟。
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
日内区间
当前US$26.58
52周区间
当前US$26.58
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3.76亿 USD | 1.97亿 USD | 5960.6万 USD | 368.6万 USD | — |
| 销货成本 | 3669.5万 USD | 1912.8万 USD | 498.7万 USD | 75.4万 USD | 76.3万 USD |
| 毛利 | 3.39亿 USD | 1.77亿 USD | 5461.9万 USD | 293.2万 USD | −76.3万 USD |
| 研究与开发 | 7705.1万 USD | 7642万 USD | 1.11亿 USD | 1.82亿 USD | 1.46亿 USD |
| 销售、一般及管理费用 | 2.75亿 USD | 2.29亿 USD | 1.85亿 USD | 1.22亿 USD | 6097.1万 USD |
| 营业费用 | 3.52亿 USD | 3.06亿 USD | 2.96亿 USD | 3.05亿 USD | 2.06亿 USD |
| 利息收入 | — | — | — | — | 17.3万 USD |
| 利息支出 | 1208.3万 USD | 2716.8万 USD | 2971.2万 USD | 1565.2万 USD | — |
| 折旧和摊销 | 466.7万 USD | 259.9万 USD | 75万 USD | 93.4万 USD | 45.4万 USD |
| 营业利润 | −1222.7万 USD | −1.28亿 USD | −2.41亿 USD | −3.02亿 USD | −2.07亿 USD |
| 净利润 | −1614.1万 USD | −1.4亿 USD | −2.62亿 USD | −3.11亿 USD | −2.06亿 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$38.33
上涨空间 44.21%报告持有此股票敞口的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR1.67亿0.16%1031.91亿 USD0.06%US$137.55+0.17%
Vanguard Morningstar Total Stock Market ETFVTI8568.37万0.00%2.3万亿 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI7496.49万0.76%98.74亿 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM7368.58万0.09%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF3171.97万0.03%954亿 USD0.05%US$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM2589.61万0.16%158.4亿 USD0.03%US$53.45+0.17%
iShares Russell 2000 Growth ETFIWO2588.38万0.19%139.17亿 USD0.24%US$356.78+0.94%
Simplify Health Care ETFPINK2106.7万6.60%3.19亿 USD0.51%US$38.527+2.57%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Russell 2000 Growth ETFIWOSimplify Health Care ETFPINKAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
